{"nctId":"NCT03689946","briefTitle":"Effect of Evolocumab on Coronary Atherosclerosis","startDateStruct":{"date":"2019-03-19","type":"ACTUAL"},"conditions":["Cardiovascular Disease","Hyperlipidemia"],"count":55,"armGroups":[{"label":"Evolocumab, F18-NaF PET, CCTA","type":"EXPERIMENTAL","interventionNames":["Drug: Evolocumab","Diagnostic Test: 18F-NaF PET","Diagnostic Test: CCTA","Drug: Omnipaque","Drug: Metoprolol","Drug: Nitroglycerin"]}],"interventions":[{"name":"Evolocumab","otherNames":["RepathaÂ®","PCSK9 inhibitor"]},{"name":"18F-NaF PET","otherNames":["18F sodium fluoride","sodium fluoride PET"]},{"name":"CCTA","otherNames":["Coronary computed tomography angiography"]},{"name":"Omnipaque","otherNames":["contrast"]},{"name":"Metoprolol","otherNames":["beta blocker"]},{"name":"Nitroglycerin","otherNames":["vasodilator"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Evidence by CCTA of noncalcified coronary artery plaque (\\>440 mm3) and thoracic aorta atherosclerosis\n* On-label indications for evolocumab treatment which includes the following criteria:\n\nThose who have established cardiovascular disease defined as acute coronary syndrome, history of myocardial infarction, stable angina or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin.\n\nExclusion Criteria:\n\n* Creatinine \\> 1.5 mg/dL prior to imaging\n* History of allergy to iodine contrast agents\n* Allergy to evolocumab or any other ingredients contained in study drug\n* Pregnancy\n* Women who are breastfeeding\n* Active atrial fibrillation\n* History of coronary artery bypass graft\n* Inability to lie flat\n* Inability or unwilling to give informed consent\n* Major illness or life expectancy \\<1 year\n* Planned coronary revascularization or major non-cardiac surgery in the next 12 months\n* Previously or currently on evolocumab","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Noncalcified Coronary Artery Plaque Volume (NCPV)","description":"Compare NCPV in mm\\^3 measured on cardiac CT images as analyzed by quantitative software between the two assessments","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45","spread":"64"}]}]}]},{"type":"SECONDARY","title":"Change in Plaque Composition (Total, Calcified, Low Density Non Calcified)","description":"Chances in volume of type of plaque (total, calcified, low density non calcified) on cardiac CT images as detected by quantitative software between the two assessments","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":"56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17","spread":"24"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":["runny nose"]}}}